Absci Shares Hit Four-Year High After Leerink Partners Initiates Coverage
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Analyst Rating Upgrade: Leerink Partners initiated coverage on Absci (ABSI) with an Outperform rating, highlighting the company's attractive catalyst path in AI-driven drug development, which is expected to drive stock price increases.
- Clinical Trial Progress: Absci's lead asset, ABS-201, an AI-designed long-acting antibody targeting the prolactin receptor, is set to undergo a Phase 2 trial for endometriosis in Q4 2026, potentially opening significant market opportunities for the company.
- Data Release Expectations: The ongoing Phase 1/2 trial for ABS-201 targeting androgenetic alopecia is expected to yield preliminary and interim proof-of-concept data in Q2 and H2 2026, respectively, providing crucial support for the company's future R&D directions.
- Target Price Set: The analyst set a $12 target price for Absci's stock, arguing that while the forward 18-month catalyst path is highly binary, it remains one of the most attractive investment opportunities within their coverage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABSI
Wall Street analysts forecast ABSI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.940
Low
4.32
Averages
7.66
High
10.00
Current: 5.940
Low
4.32
Averages
7.66
High
10.00
About ABSI
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Absci Shares Hit Four-Year High After Leerink Partners Initiates Coverage
- Analyst Rating Upgrade: Leerink Partners initiated coverage on Absci (ABSI) with an Outperform rating, highlighting the company's attractive catalyst path in AI-driven drug development, which is expected to drive stock price increases.
- Clinical Trial Progress: Absci's lead asset, ABS-201, an AI-designed long-acting antibody targeting the prolactin receptor, is set to undergo a Phase 2 trial for endometriosis in Q4 2026, potentially opening significant market opportunities for the company.
- Data Release Expectations: The ongoing Phase 1/2 trial for ABS-201 targeting androgenetic alopecia is expected to yield preliminary and interim proof-of-concept data in Q2 and H2 2026, respectively, providing crucial support for the company's future R&D directions.
- Target Price Set: The analyst set a $12 target price for Absci's stock, arguing that while the forward 18-month catalyst path is highly binary, it remains one of the most attractive investment opportunities within their coverage.
See More
SPDR S&P Oil & Gas ETF Underperforms
- ETF Performance: The SPDR S&P Oil & Gas Equipment & Services ETF is down approximately 1.8% in Thursday afternoon trading, indicating market concerns about the sector that could impact investor confidence.
- Weak Individual Stocks: Within the ETF, Atlas Energy Solutions shares fell about 6%, while Flowco Holdings dropped approximately 4.7%, reflecting poor market performance for these companies that may lead investors to reassess their portfolios.
- Market Sentiment Impact: The overall weak performance of the oil and gas sector may cause investors to adopt a cautious stance towards related stocks, potentially affecting capital inflows into the industry.
- Uncertain Industry Outlook: Given the current economic environment, the oil and gas equipment and services sector faces challenges that could suppress the ETF's long-term performance, prompting investors to monitor industry developments for informed decision-making.
See More
Absci's Experimental Hair Loss Treatment Gains Wall Street Favor
- Market Potential: BTIG initiated coverage of Absci Corporation with a buy rating and a 12-month price target of $9, projecting peak sales of its AI-designed antibody ABS-201 for hair loss could reach $2.2 billion, highlighting the product's significant potential in an underserved market.
- Innovative Mechanism: ABS-201 is touted as the first new mechanism in androgenetic alopecia in nearly three decades, with Absci establishing a clinical advisory board for the program, indicating the company's commitment and strategic planning for future development.
- Technological Moat: Absci's AI platform is described by BTIG as a
See More
Key Wall Street Ratings Updates for Thursday
- Tesla Robotaxi Expansion: Morgan Stanley reiterates Tesla as equal weight, noting survey checks indicate increased hiring of 'AI Safety Operators' in northern metro areas, suggesting Tesla is gearing up for robotaxi operations expansion, which could enhance future revenues.
- National Health Properties Outlook: Citizens initiates coverage of National Health Properties as outperform, believing the REIT is enhancing organic growth by increasing exposure to Senior Housing Operating Properties, indicating confidence in the senior living market.
- Nvidia Data Center Potential: Bernstein reiterates Nvidia as outperform, highlighting the enormous and still early datacenter opportunity, which is expected to provide significant upside, reflecting optimism in tech stocks.
- Quanta Services Rating Upgrade: Oppenheimer upgrades Quanta Services from perform to outperform with an $800 price target, indicating strong growth potential in the coming years, particularly in adjusted EBITDA expectations.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Absci Shares Hit Four-Year High After Leerink Partners Initiates Coverage
- Analyst Rating Upgrade: Leerink Partners initiated coverage on Absci (ABSI) with an Outperform rating, highlighting the company's attractive catalyst path in AI-driven drug development, which is expected to drive stock price increases.
- Clinical Trial Progress: Absci's lead asset, ABS-201, an AI-designed long-acting antibody targeting the prolactin receptor, is set to undergo a Phase 2 trial for endometriosis in Q4 2026, potentially opening significant market opportunities for the company.
- Data Release Expectations: The ongoing Phase 1/2 trial for ABS-201 targeting androgenetic alopecia is expected to yield preliminary and interim proof-of-concept data in Q2 and H2 2026, respectively, providing crucial support for the company's future R&D directions.
- Target Price Set: The analyst set a $12 target price for Absci's stock, arguing that while the forward 18-month catalyst path is highly binary, it remains one of the most attractive investment opportunities within their coverage.
See More
SPDR S&P Oil & Gas ETF Underperforms
- ETF Performance: The SPDR S&P Oil & Gas Equipment & Services ETF is down approximately 1.8% in Thursday afternoon trading, indicating market concerns about the sector that could impact investor confidence.
- Weak Individual Stocks: Within the ETF, Atlas Energy Solutions shares fell about 6%, while Flowco Holdings dropped approximately 4.7%, reflecting poor market performance for these companies that may lead investors to reassess their portfolios.
- Market Sentiment Impact: The overall weak performance of the oil and gas sector may cause investors to adopt a cautious stance towards related stocks, potentially affecting capital inflows into the industry.
- Uncertain Industry Outlook: Given the current economic environment, the oil and gas equipment and services sector faces challenges that could suppress the ETF's long-term performance, prompting investors to monitor industry developments for informed decision-making.
See More
Absci's Experimental Hair Loss Treatment Gains Wall Street Favor
- Market Potential: BTIG initiated coverage of Absci Corporation with a buy rating and a 12-month price target of $9, projecting peak sales of its AI-designed antibody ABS-201 for hair loss could reach $2.2 billion, highlighting the product's significant potential in an underserved market.
- Innovative Mechanism: ABS-201 is touted as the first new mechanism in androgenetic alopecia in nearly three decades, with Absci establishing a clinical advisory board for the program, indicating the company's commitment and strategic planning for future development.
- Technological Moat: Absci's AI platform is described by BTIG as a
See More
Key Wall Street Ratings Updates for Thursday
- Tesla Robotaxi Expansion: Morgan Stanley reiterates Tesla as equal weight, noting survey checks indicate increased hiring of 'AI Safety Operators' in northern metro areas, suggesting Tesla is gearing up for robotaxi operations expansion, which could enhance future revenues.
- National Health Properties Outlook: Citizens initiates coverage of National Health Properties as outperform, believing the REIT is enhancing organic growth by increasing exposure to Senior Housing Operating Properties, indicating confidence in the senior living market.
- Nvidia Data Center Potential: Bernstein reiterates Nvidia as outperform, highlighting the enormous and still early datacenter opportunity, which is expected to provide significant upside, reflecting optimism in tech stocks.
- Quanta Services Rating Upgrade: Oppenheimer upgrades Quanta Services from perform to outperform with an $800 price target, indicating strong growth potential in the coming years, particularly in adjusted EBITDA expectations.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
